T cells redirected to interleukin-13Rα2 with interleukin-13 mutein–chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1
Background aims Outcomes for patients with glioblastoma remain poor despite aggressive
multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric
antigen receptors (CARs) targeting interleukin (IL) 13Rα2, human epidermal growth factor
receptor 2, epidermal growth factor variant III or erythropoietin-producing hepatocellular
carcinoma A2 has shown promise for the treatment of glioma in preclinical models. On the
basis of IL13Rα2 immunotoxins that contain IL13 molecules with one or two amino acid …
multimodal therapy. Immunotherapy with genetically modified T cells expressing chimeric
antigen receptors (CARs) targeting interleukin (IL) 13Rα2, human epidermal growth factor
receptor 2, epidermal growth factor variant III or erythropoietin-producing hepatocellular
carcinoma A2 has shown promise for the treatment of glioma in preclinical models. On the
basis of IL13Rα2 immunotoxins that contain IL13 molecules with one or two amino acid …